secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nutex Health Inc. (NUTX)
CIK:        0001479681
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001628280-26-015174
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nutex Health FY2025 revenue up 82% to $875M, diluted EPS $10.48; announces $25M buyback
--------------------------------------------------------------------------------

- FY2025 total revenue $875.3M, up 82.4% YoY; net income $70.8M vs $52.1M; diluted EPS $10.48 vs $9.69.
- Q4 revenue $151.7M (-41.1% YoY) due to $55M arbitration true-up and $69M arbitration revenue recorded in Q4 2024.
- Q4 net income $11.8M vs $61.6M; EBITDA $25.7M vs $78.9M; Adjusted EBITDA $16.6M vs $86.7M.
- Board authorized $25M stock repurchase program over 6 months to offset dilution from earn-out shares for hospitals.
- Remediated all previously disclosed material weaknesses in internal controls over financial reporting in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479681/000162828026015174/0001628280-26-015174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479681/000162828026015174/nutx-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-015174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer